Related Experiment Video
Updated: May 12, 2025
08:41
Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
Published on: June 7, 2017
8.2K
Decoding the resistin-CAP1 pathway in intermediate monocytes mediating liver allograft rejection
Peijun Yang1, Xudan Wang2, Weikang Wu2
1Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China; Second Department of Hepatopancreatobiliary Surgery, China-Japan Friendship Hospital, Beijing, 100029, China.
Journal of Hepatology
|May 9, 2025
Summary
Researchers identified intermediate monocytes and the Resistin-CAP1 pathway as key drivers of liver transplant rejection. Targeting this pathway with nanogold-siRNA technology effectively reduced rejection and improved graft survival in rats.
Area of Science:
- Immunology
- Transplantation Biology
- Genomics
Background:
- Lymphocytes mediate liver transplant rejection, but current treatments have limitations.
- Novel immunotherapeutic targets are needed to improve transplant outcomes.
- Conventional immunosuppressants cause severe side effects.
Purpose of the Study:
- To investigate the immune cell dynamics and molecular mechanisms underlying liver allograft rejection.
- To identify novel cellular and molecular targets for mitigating transplant rejection.
- To explore the role of the Resistin-CAP1 pathway in T cell-mediated rejection.
Main Methods:
- Single-cell RNA sequencing and spatial transcriptomics were used on rat liver transplant samples.
- Flow cytometry and recombinant assays validated Resistin's role in T-cell function.
- Gold nanoparticles delivered Retn siRNA to assess knockdown effects on rejection.
Main Results:
- Intermediate monocytes were identified as critical in cellular rejection.
- The Resistin-CAP1 pathway was implicated in T cell-mediated rejection.
- Resistin knockdown using nanogold-siRNA significantly reduced acute rejection and extended graft survival in rats.
Conclusions:
- Intermediate monocytes and the Resistin-CAP1 axis are key players in liver transplant rejection.
- Targeting Resistin offers a promising immunotherapeutic strategy for allograft rejection.
- This study advances diagnostic and therapeutic approaches for liver transplantation.
